Hologic Granted FDA Emergency Use Authorization for Its Second Molecular Test for COVID-19

Significant Test Manufacturing Capacity, Large Installed Base of Automated Instruments Yield Testing Breakthrough

MARLBOROUGH, MA (STL.News) Hologic, Inc. (Nasdaq: HOLX) announced today that it has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for its Aptima SARS-CoV-2 assay to detect the novel coronavirus.

The newly authorized test runs on Hologic’s fully automated Panther® system, more than 1,000 of which are already installed in clinical laboratories throughout the United States.  Each Panther system can provide initial results in approximately three hours and process more than 1,000 coronavirus tests in 24 hours.  Hologic has begun distributing its new coronavirus test, and expects to produce an average of one million tests per week.  Combining significant manufacturing capacity for the new test with the world’s largest installed base of high-throughput molecular instruments is expected to dramatically increase testing capabilities.

“Delivering test results when and where they are needed – so people can either get back to work or quarantine themselves – is key to re-opening global economies safely,” said Steve MacMillan, the Company’s Chairman, President and CEO.  “I’m so proud of the incredible teamwork across the company that brought this test to market so quickly.”

The Panther system is a fully automated, high-throughput molecular diagnostic platform that is widely used around the world, with more than 1,800 systems installed in 60 countries.  In the United States, instruments are installed across all 50 states.  Approximately 750 U.S. hospital, public health and reference labs use the Panther system and its suite of Aptima assays to perform tens of millions of molecular tests annually for sexually transmitted infections, cervical cancer screening and viral load monitoring in people with HIV and hepatitis.

Certain aspects of the Aptima SARS-CoV-2 assay project were conducted under a $13 million contract, initially announced on April 29, 2020, with the Biomedical Advanced Research and Development Authority, part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services.

Hologic plans to register its Aptima SARS-CoV-2 assay for a CE Mark for diagnostic use in Europe later in May.